CTI BioPharma clinical trials

Acquired by Swedish Orphan Biovitrum, Jun 24, 2023 · source ↗

The registry lists 38 studies whose lead sponsor is CTI BioPharma. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 21, 2024.

Studies

Recruiting first, then most recently updated. Showing 38 of 38. All Swedish Orphan Biovitrum studies →

• Study to Evaluate the Safety, Tolerability, and PK of PacritinibCompletedNCT05552183Phase 1

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male SubjectsCompletedNCT05657613Phase 1

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without CancerTerminatedNCT04404361Phase 2

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against DoxorubicinCompletedNCT00268853Phase 2

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic ImpairmentWithdrawnNCT01632436Phase 1

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)CompletedNCT00106600Phase 1/2

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• Crossover Trial of the Effect of a High-Fat Meal on the PK of Oral CHR 2797 in Healthy Male SubjectsCompletedNCT01638442Phase 1

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy SubjectsCompletedNCT02807116Phase 1

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy SubjectsCompletedNCT02808455Phase 1

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy SubjectsCompletedNCT02807207Phase 1

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy SubjectsCompletedNCT02823171Phase 1

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With RuxolitinibCompletedNCT04884191Phase 2

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell TransplantCompletedNCT01321541Phase 3

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and ThrombocytopeniaTerminatedNCT02055781Phase 3

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.TerminatedNCT00269828Phase 3

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous TherapyTerminatedNCT00004026Phase 2

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mLWithdrawnNCT00576225Phase 3

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin LymphomaWithdrawnNCT00551239Phase 3

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• Arsenic Trioxide in Treating Patients With Multiple MyelomaTerminatedNCT00017433Phase 2

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple MyelomaTerminatedNCT00017069Phase 2

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• Arsenic Trioxide in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00020969Phase 2

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung CancerTerminatedNCT00054210Phase 3

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung CancerTerminatedNCT00054184Phase 3

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHLWithdrawnNCT00577161Phase 3

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerTerminatedNCT00551733Phase 3

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung CancerTerminatedNCT00054197Phase 3

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• Pacritinib Versus Best Available Therapy to Treat MyelofibrosisTerminatedNCT01773187Phase 3

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy SubjectsCompletedNCT02765724Phase 1

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)CompletedNCT00088530Phase 3

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory CancerWithdrawnNCT02800889Phase 1

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy SubjectsCompletedNCT02807051Phase 1

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy SubjectsCompletedNCT02807077Phase 1

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• Investigate Absorption, Metabolism, Excretion, and Mass Balance of PacritinibCompletedNCT02803762Phase 1

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's LymphomaCompletedNCT00060684Phase 1

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's LymphomaTerminatedNCT00060671Phase 3

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• Phase I/II CT 2106 and 5-FU/FA in Colorectal CancerCompletedNCT00291785Phase 1/2

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• CT-2106 for the Second Line Treatment of Ovarian CancerCompletedNCT00291837Phase 2

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum

• Phase II CT-2103/Carboplatin in Ovarian CancerCompletedNCT00069901Phase 2

  Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum